Glomerulonephritis, Membranous Nephropathy, Nephrotic Syndrome
Conditions
Keywords
nephrotic syndrome, Helicobacter pylori infection, proteinuria, membranous nephropathy
Brief summary
Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.
Detailed description
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. It is thought to be mainly a primary or idiopathic form; however, it may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.
Interventions
DRUGlansoprazole, amoxicillin, clarithromycin
lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Sponsors
Istanbul University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18-70 years * Nondiabetic patients * Patients with primary glomerulonephritis * Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy * Glomerular filtration rate \> 30 mL/min * Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study
Exclusion criteria
* Patients with secondary glomerulonephritis * Glomerular filtration rate \< 30 mL/min * Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study * Patients with a history of gastric surgery * Patients without an informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily proteinuria levels after Helicobacter Pylori eradication treatment | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate | 6 months |
| Serum creatinine level | 6 months |
Countries
Turkey (Türkiye)
Outcome results
None listed